Institution identification

PURI

https://redirect.ema.europa.eu/resource/3331483

Institution ID

3331483

Institution full name and acronym

University of Oslo

ENCePP partner

No
Institution details
Experience with collecting data directly from individual patients or respondents:
No
Interest in carrying out research that is funded by pharmaceutical companies:
No

Studies conducted by the institution

A Post-Authorisation Safety Study (PASS) of ABRYSVO (Respiratory Syncytial Virus Stabilised Prefusion Subunit Vaccine) in Pregnant Women and their Offspring in a Real World Setting in Europe and UK
ADEPT: feasibility of estimating the risk of adverse pregnancy, neonatal and child outcomes following either in utero ASM exposure through the mother, or peri-conceptional ASM exposure through the father
CONSIGN study: COVID-19 infection and medicines in pregnancy - a multinational registry based study
Demonstrating solutions for studying intermittent medication exposures in diseases with episodic manifestations during pregnancy: application to medication for migraine in pregnancy
Description of international collaboration in the area of medicines use and effects in COVID-19 affected pregnancies (CONSIGN-International))
Exposure to SSRI/SNRI and depression in pregnancy and long-term childhood outcomes: the effect of modifying factors
Monitoring safety of Spikevax in pregnancy: an observational study using routinely collected health data in five European countries (COVID-19)
mRNA-1273-P910: Clinical course, outcomes and risk factors of myocarditis and pericarditis following administration of Moderna vaccines targeting SARS-CoV-2.
Post-Authorization Active Surveillance Safety Study Using Secondary Data to Monitor Real-World Safety of Spikevax in Europe (COVID-19)
SAFETY-VAC: Background incidence estimation of flares of pre-existing chronic diseases using pan-European electronic healthcare data sources. (SAFETY VAC)
SAFETY-VAC: Network of Data Sources for Vaccine Safety Evaluation
SAFETY-VAC: Phenotype proposal and rates of immunocompromised populations in real-world data sources.